IHC - ps2 Test, Price, Normal Range | Sprint Diagnostics Hyderabad

No, fasting is not required for this test as it utilizes tissue samples, not blood.

The IHC - PS2 test is typically recommended after a breast cancer diagnosis to assess the hormone sensitivity of the cancer and to aid in determining the most effective treatment strategy.

The test detects the presence of PS2 protein in breast cancer tissue. The presence of this protein can indicate that the cancer is likely to respond to hormone therapy.

This test is usually conducted once, following a breast cancer diagnosis. However, further testing may be recommended based on individual treatment response and progress.

As this test is performed on cancerous tissue, there aren't standard "normal" values. The presence or absence of PS2 proteins is interpreted by a healthcare professional in conjunction with other diagnostic information.

No specific precautions are required before this test. Patients should continue their usual diet and medications unless otherwise directed by their healthcare provider.

Age, genetic factors, and hormone therapy could potentially impact PS2 levels.

Abnormal results should be discussed with the oncologist or the healthcare provider who ordered the test. They can provide an interpretation of the results and discuss the next steps in treatment.

Risks associated with this test are typically related to the biopsy procedure, including discomfort, bruising, or potential infection at the biopsy site.

Yes, hormone therapies and other medications could potentially affect the test results.

No, the IHC - PS2 test isn't used to diagnose breast cancer. It's used to determine hormone sensitivity after a cancer diagnosis.

A positive result indicates that the cancer cells may be sensitive to hormone therapies such as Tamoxifen or Aromatase inhibitors. Your healthcare provider will discuss suitable treatment options based on the test results and overall health condition.

Yes, the IHC - PS2 test is usually done along with other tests like the Estrogen Receptor (ER) test, Progesterone Receptor (PR) test, and HER2 test to provide a comprehensive analysis of the cancer.

The test is performed by a pathologist in a laboratory setting.

Yes, while breast cancer is more common in women, men can also get it. If a man is diagnosed with breast cancer, the IHC - PS2 test can help in tailoring the treatment plan.

The IHC - PS2 test is predominantly used in the context of breast cancer. However, PS2 protein expression may also be studied in other hormone-responsive cancers.

Lifestyle changes can improve overall health and aid in managing many types of illnesses, but the presence or absence of PS2 proteins in cancer cells is primarily determined by the cancer's inherent characteristics and is not directly impacted by lifestyle changes.

The test itself is not painful, but the biopsy procedure used to collect the tissue sample can cause some discomfort.

Yes, if the test is positive, indicating the presence of PS2 protein, the cancer is likely to respond to certain hormone therapies, leading to a potentially better treatment outcome.

In conclusion, the IHC - PS2 (Estrogen Regulated Protein) Diagnostic Test is a valuable tool for managing hormone-sensitive breast cancers. It is important to discuss the results with your healthcare provider to understand the implications and to decide on the most appropriate course of action. Open and continuous communication with your healthcare provider can lead to a better understanding of your condition and contribute to a more effective treatment plan.